Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 9/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4053927 | 0.95 | BRAF (0.50) | BRAFMAPTTDP1MAPK14 | |
| SCHEMBL4051286 | 0.89 | BRAF (0.51) | BRAFMAPTTDP1MAPK14 | |
| SCHEMBL4053112 | 0.89 | BRAF (0.51) | BRAFMAPK14 | |
| SCHEMBL4056272 | 0.87 | BRAF (0.53) | BRAFMAPTTDP1MAPK14 | |
| SCHEMBL4058317 | 0.86 | BRAF (0.57) | BRAFMAPTTDP1MAPK14 | |
| SCHEMBL4050676 | 0.86 | BRAF (0.51) | BRAFMAPTTDP1MAPK14 | |
| SCHEMBL4056404 | 0.84 | BRAF (0.50) | BRAFMAPK14 | |
| SCHEMBL4051193 | 0.82 | BRAF (0.51) | BRAFMAPTTDP1MAPK14 | |
| SCHEMBL4049503 | 0.81 | BRAF (0.51) | BRAFMAPTTDP1MAPK14 | |
| SCHEMBL4051671 | 0.79 | BRAF (0.49) | BRAFMAPTTDP1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009111260-A1 | PHENYLSULFONAMIDE-SUBSTITUTED, PYRAZOLO[1, 5-A]PYRIMIDINES, METHODS FOR PREPARATION AND USES THEREOF | WYETH (US) | 2009-09-11 | — | — | WO | claimed |
| WO-2009111260-A1 | PHENYLSULFONAMIDE-SUBSTITUTED, PYRAZOLO[1, 5-A]PYRIMIDINES, METHODS FOR PREPARATION AND USES THEREOF | WYETH (US) | 2009-09-11 | — | — | WO | disclosed |